William Cliby

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function
    William A Cliby
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 277:1599-606. 2002
  2. ncbi request reprint Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
    William A Cliby
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 103:797-801. 2006
  3. ncbi request reprint Abdominal incision wound breakdown
    William A Cliby
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Obstet Gynecol 45:507-17. 2002
  4. ncbi request reprint Diaphragm resection for ovarian cancer: technique and short-term complications
    William Cliby
    Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, United States
    Gynecol Oncol 94:655-60. 2004
  5. pmc The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer
    Gretchen Glaser
    Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 130:280-3. 2013
  6. pmc Metformin intake is associated with better survival in ovarian cancer: a case-control study
    Sanjeev Kumar
    Department of Gynecologic Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer 119:555-62. 2013
  7. pmc Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma
    Sean C Dowdy
    Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 109:303-7. 2008
  8. doi request reprint Incidence and timing of venous thromboembolism after surgery for gynecological cancer
    Abraham Peedicayil
    Department of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 121:64-9. 2011
  9. ncbi request reprint Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 105:84-9. 2007
  10. ncbi request reprint Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Obstet Gynecol 195:1862-8. 2006

Research Grants

Collaborators

Detail Information

Publications51

  1. ncbi request reprint S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function
    William A Cliby
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 277:1599-606. 2002
    ....
  2. ncbi request reprint Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
    William A Cliby
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 103:797-801. 2006
    ..A subset of patients is upstaged to Stage IIIC because of lymph node metastases, in which prognosis is not well defined. We undertook this study to describe the clinical behavior of occult Stage IIIC...
  3. ncbi request reprint Abdominal incision wound breakdown
    William A Cliby
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Obstet Gynecol 45:507-17. 2002
  4. ncbi request reprint Diaphragm resection for ovarian cancer: technique and short-term complications
    William Cliby
    Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, United States
    Gynecol Oncol 94:655-60. 2004
    ..Oncol. 82 (2001) 489). The aim of this study was to assess postoperative complications of DR in OC...
  5. pmc The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer
    Gretchen Glaser
    Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 130:280-3. 2013
    ..We performed a pilot study of whether CT findings could predict extent of disease and surgical complexity necessary in advanced OC...
  6. pmc Metformin intake is associated with better survival in ovarian cancer: a case-control study
    Sanjeev Kumar
    Department of Gynecologic Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer 119:555-62. 2013
    ..The objective of this case-control study was to identify any association of metformin intake with the survival of patients with ovarian cancer...
  7. pmc Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma
    Sean C Dowdy
    Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 109:303-7. 2008
    ..To describe the technique of diaphragmatic peritonectomy (DP) for ovarian cancer cytoreduction and to assess associated morbidity...
  8. doi request reprint Incidence and timing of venous thromboembolism after surgery for gynecological cancer
    Abraham Peedicayil
    Department of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 121:64-9. 2011
    ..This study aims to determine the incidence, timing, and risk factors of clinical venous thromboembolism...
  9. ncbi request reprint Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 105:84-9. 2007
    ..Determine impact of tumor distribution and surgery on prognosis in patients with stage IV epithelial ovarian cancer (EOC)...
  10. ncbi request reprint Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Obstet Gynecol 195:1862-8. 2006
    ..The purpose of this study was to determine the factors that are related to the performance of lymph node assessment and its impact on prognosis in ovarian cancer...
  11. ncbi request reprint A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 107:99-106. 2007
    ..To test the feasibility and utility of a risk-adjusted, multicenter outcomes model for ovarian cancer surgery as a tool for quality improvement...
  12. ncbi request reprint Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
    Giovanni D Aletti
    Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 104:212-6. 2007
    ..Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the "time to chemotherapy" (TTC) interval on survival...
  13. pmc Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity
    Jeremy Chien
    Department of Laboratory Medicine and Experimental Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA, Medical Oncology Unit and Department of Histopathology, San Salvatore Hospital, Pesaro, Italy
    J Clin Invest 116:1994-2004. 2006
    ....
  14. ncbi request reprint Importance of surgical aggressiveness in advanced ovarian cancer
    Giovanni D Aletti
    J Clin Oncol 24:2397; author reply 2398-9. 2006
  15. ncbi request reprint Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva
    Jesus Gonzalez Bosquet
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Surgery, Mayo Clinic Rochester, SW Rochester, MN 55905, USA
    Gynecol Oncol 105:742-6. 2007
    ..Assess whether the identified pattern of lymphatic spread supports the current surgical practice of assessing contralateral nodes for lateral lesions with ipsilateral nodal involvement...
  16. ncbi request reprint Current management strategies for ovarian cancer
    Giovanni D Aletti
    Division of Gynecologic Surgery, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:751-70. 2007
    ..In this review, we provide an overview of ovarian cancer with particular emphasis on recent advances in operative management and systemic therapies...
  17. ncbi request reprint Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers
    Taufika Islam Williams
    W M Keck FT ICR Mass Spectrometry Laboratory, Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, USA
    J Proteome Res 6:2936-62. 2007
    ..Current methods of detection and therapy are discussed. A survey of promising new protein, gene, and metabolite biomarkers on the horizon is provided. Future prospects for improved diagnosis are offered...
  18. ncbi request reprint Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma
    M Bijoy Thomas
    Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 107:186-9. 2007
    ..To assess surgical staging with systematic lymphadenectomy (LND) and adjuvant therapy in patients with stage I uterine papillary serous carcinoma (UPSC)...
  19. ncbi request reprint Treatment of pulmonary recurrences in patients with endometrial cancer
    Sean C Dowdy
    Division of Gynecologic Surgery, Mayo Clinic, 200 1st St NW, Rochester, MN 55905, USA
    Gynecol Oncol 107:242-7. 2007
    ..To assess the treatment and outcome of patients with endometrial cancer following isolated pulmonary relapse...
  20. ncbi request reprint Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers
    Kriste A Lewis
    Department of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Genes Chromosomes Cancer 46:1061-8. 2007
    ..4/18 recurrences in MSI-H cases without ATR mutations. This suggests that ATR mutations may affect clinical behavior and response to therapy in MSI-H colon cancers...
  21. ncbi request reprint Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers
    Jamie N Bakkum-Gamez
    Department of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 108:141-8. 2008
    ..Secondarily, we examined the impact of MISIIR expression on overall survival (OS) and disease-free survival (DFS) in a cohort of epithelial ovarian cancers (EOC)...
  22. ncbi request reprint Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Obstet Gynecol 197:676.e1-7. 2007
    ..However, the trade-off between short-term morbidity and overall survival is complex, and few data are available analyzing the combined effects of these variables...
  23. pmc Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging
    Andrea Mariani
    Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gynecol Oncol 109:11-8. 2008
    ..To prospectively assess pelvic and para-aortic lymph node metastases in endometrial cancer with lymphatic dissemination, emphasizing the examination of para-aortic metastases relative to the inferior mesenteric artery (IMA)...
  24. ncbi request reprint Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival
    Larry M Karnitz
    Division of Oncology Research, Guggenheim 13, Mayo Clinic College of Medicine, 200 First Street, S W, Rochester, Minnesota 55905, USA
    Mol Pharmacol 68:1636-44. 2005
    ....
  25. ncbi request reprint Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients
    Andrea Mariani
    Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 101:200-8. 2006
    ..To assess the efficacy of systematic lymphadenectomy and adjuvant radiotherapy in minimizing pelvic sidewall and para-aortic failures...
  26. ncbi request reprint Aggressive surgical effort and improved survival in advanced-stage ovarian cancer
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Obstet Gynecol 107:77-85. 2006
    ..However, the extent of surgical resection required to achieve optimal cytoreduction is controversial. Our goal was to estimate the effect of aggressive surgical resection on ovarian cancer patient survival...
  27. ncbi request reprint Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage
    Christopher E Helt
    Department of Environmental Medicine, School of Medicine and Dentistry, The University of Rochester, Rochester, New York 14642, USA
    J Biol Chem 280:1186-92. 2005
    ..These data reveal activated ATM and ATR exhibit selective substrate specificity in response to different genotoxic agents...
  28. ncbi request reprint Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry
    H Robert Bergen
    W M Keck FT ICR Mass Spectrometry Laboratory, Mayo Proteomics Research Center, Rochester, MN, USA
    Dis Markers 19:239-49. 2003
    ..One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states...
  29. ncbi request reprint Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells
    Kimberly R Kalli
    Division of Endocrinology, Metabolism and Nutrition, Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Int J Cancer 110:633-40. 2004
    ..The concurrent regulation of PAPP-A and its inhibitor, proMBP, suggests that IGFBP-4 proteolysis and local regulation of IGF availability may be altered in malignant ovarian epithelial cells...
  30. ncbi request reprint Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer
    Jesus Gonzalez Bosquet
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 91:518-25. 2003
    ..This was a pilot study to determine whether cytokeratin staining of LN from endometrial cancer patients is more sensitive than traditional histopathologic evaluation for the detection of micrometastasis...
  31. pmc Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literature
    Paul M Magtibay
    Division of Gynecologic Oncology, Department of Obstetrics Gynecolory, Mayo Graduate School of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neuro Oncol 5:217-20. 2003
    ..We conclude that adult onset medulloblastoma with metastasis to the peritoneal cavity is rare and may be associated with a VP shunt...
  32. ncbi request reprint Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy
    Prema P Peethambaram
    Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 89:99-104. 2003
    ..Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy...
  33. ncbi request reprint Hepatic resection for metachronous metastases from ovarian carcinoma
    Melissa A Merideth
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 89:16-21. 2003
    ..To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment...
  34. ncbi request reprint P2X(3) receptor subunit messenger RNA expression in the female mouse bladder after oophorectomy with or without estrogen replacement
    Michael E Carley
    Departments of Obstetrics and Gynecology, Division of Gynecological Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Am J Obstet Gynecol 187:103-6. 2002
    ....
  35. ncbi request reprint Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
    ..We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy...
  36. ncbi request reprint Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes
    Sean C Dowdy
    Division of Gynecologic Surgery, 200 1st St NW, Rochester, MN 55905, USA
    Gynecol Oncol 101:280-6. 2006
    ..To describe the technique and assess outcomes and morbidity following radical resection combined with intraoperative electron radiation therapy (IOERT) in patients with recurrent endometrial cancer...
  37. ncbi request reprint Elevated fibroblast growth factor 23 in women with malignant ovarian tumors
    Peter J Tebben
    Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:745-51. 2005
    ..To determine whether fibroblast growth factor 23 (FGF23) concentrations are altered in women with ovarian cancers in which FGF physiology is known to be abnormal...
  38. ncbi request reprint Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance
    Kriste A Lewis
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 65:7091-5. 2005
    ..These findings imply that ATR mutations play an important role in the development and clinical behavior of a subset of microsatellite instability-positive endometrial, colon, and stomach cancers...
  39. ncbi request reprint Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 100:283-7. 2006
    ..Lack of evidence of survival benefit, concerns over safety and lack of experience are common justifications for this belief. In this study, we sought to evaluate the therapeutic value of diaphragmatic surgery in advanced ovarian cancer...
  40. ncbi request reprint Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 100:33-7. 2006
    ..We investigated the impact of clinical and surgical-pathologic factors at the time of initial exploration on the ability to achieve optimal cytoreduction...
  41. ncbi request reprint Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva
    Jesus Gonzalez Bosquet
    Division of Gynecologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 97:828-33. 2005
    ..To assess time to failure and sites of failure with extended follow-up of patients with squamous cell carcinoma (SCC) of the vulva...
  42. ncbi request reprint Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer
    Debra L Richardson
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Gynecol Oncol 103:667-72. 2006
    ..Our objective was to identify primary risk factors for anastomotic leak in OC patients undergoing RS resection to better determine who would most benefit from protective diversion...
  43. ncbi request reprint Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer
    Giovanni D Aletti
    Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Am Coll Surg 203:521-6. 2006
    ..We evaluated the therapeutic value of this maximal surgical effort in advanced ovarian cancer...
  44. ncbi request reprint Frozen section evaluation of cervical cold knife cone specimens is accurate in the diagnosis of microinvasive squamous cell carcinoma
    Robert L Giuntoli
    Division of Gynecologic Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Gynecol Oncol 91:280-4. 2003
    ..The purpose of this study was to determine the accuracy of frozen section evaluation of cervical cold knife cone (CKC) specimens in the diagnosis of microinvasive squamous cell carcinoma (SCC)...
  45. ncbi request reprint How relevant are ACOG and SGO guidelines for referral of adnexal mass?
    Amy C Dearking
    Mayo Medical School, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA
    Obstet Gynecol 110:841-8. 2007
    ....
  46. ncbi request reprint Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
    Mory Nouriani
    Division of Gynecologic Oncology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 10:2681-6. 2004
    ..We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma...
  47. ncbi request reprint Role of bcl-2 in endometrioid corpus cancer: an experimental study
    Andrea Mariani
    Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Anticancer Res 26:823-7. 2006
    ..Bcl-2 expression appears to be under hormonal control in normal endometrium and to correlate with hormone receptor status in endometrial cancer. The aim of this study was to assess bcl-2 expression in endometrial cancer...
  48. ncbi request reprint Role of cytoreduction in stage III and IV uterine papillary serous carcinoma
    M Bijoy Thomas
    Division of Gynecologic Surgery, Mayo Clinic, 200 1st St NW, Rochester, MN 55905, USA
    Gynecol Oncol 107:190-3. 2007
    ..Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC...
  49. ncbi request reprint The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma
    Sean C Dowdy
    Department of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:346-52. 2004
    ..A predictive model using CT scanning and CA 125 values would allow the authors to determine which patients would be more appropriately treated with neoadjuvant chemotherapy...
  50. ncbi request reprint Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer
    Allison E Axtell
    University of California Los Angeles UCLA Medical Center, Los Angeles, CA, USA
    J Clin Oncol 25:384-9. 2007
    ..Reciprocally cross validate the predictors identified with those from two previously published cohorts from institutions B and C...
  51. ncbi request reprint Prevention and management of acute intraoperative bleeding
    Bobbie S Gostout
    Section of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Obstet Gynecol 45:481-91. 2002

Research Grants2

  1. ATR in Human Cancer and Anticancer Therapy
    William Cliby; Fiscal Year: 2004
    ..Using xenograft models we will develop a gene therapy model of ATR disruption to test the safety and efficacy of targeting ATR for anticancer therapy. ..
  2. Targeting the Mullerian Inhibiting Substance pathway in gynecologic cancer
    William A Cliby; Fiscal Year: 2010
    ..This projects brings together two investigators with distinctly different areas of expertise to address both the fundamental biologic aspects of the pathway and the translational aspects of targeting this receptor in cancer. ..